Captor Therapeutics Spolka Akcyjna (CTX.WA)
PLN 47.8
(5.99%)
PLN 47.8
(5.99%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 13.2 Million PLN | 44.15% |
| 2022 | 9.15 Million PLN | 129.75% |
| 2021 | 3.98 Million PLN | 0.0% |
| 2020 | - PLN | 0.0% |
| 2019 | - PLN | -100.0% |
| 2018 | 16 Thousand PLN | -96.62% |
| 2017 | 474 Thousand PLN | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 4.5 Million PLN | -30.53% |
| 2024 Q2 | 4.83 Million PLN | 7.35% |
| 2023 Q4 | 6.48 Million PLN | 130.45% |
| 2023 Q1 | 1.54 Million PLN | -73.49% |
| 2023 Q3 | 2.81 Million PLN | 19.29% |
| 2023 FY | 13.2 Million PLN | 44.15% |
| 2023 Q2 | 2.35 Million PLN | 52.88% |
| 2022 Q2 | 1.19 Million PLN | 14.96% |
| 2022 FY | 9.15 Million PLN | 129.75% |
| 2022 Q4 | 5.82 Million PLN | 424.41% |
| 2022 Q3 | 1.11 Million PLN | -6.8% |
| 2022 Q1 | 1.03 Million PLN | -19.0% |
| 2021 Q2 | 1.03 Million PLN | 142.92% |
| 2021 Q4 | 1.27 Million PLN | 2.08% |
| 2021 Q3 | 1.25 Million PLN | 21.65% |
| 2021 FY | 3.98 Million PLN | 0.0% |
| 2021 Q1 | 424 Thousand PLN | 0.0% |
| 2020 FY | - PLN | 0.0% |
| 2020 Q3 | - PLN | 0.0% |
| 2020 Q4 | - PLN | 0.0% |
| 2019 FY | - PLN | -100.0% |
| 2018 FY | 16 Thousand PLN | -96.62% |
| 2017 FY | 474 Thousand PLN | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Bioceltix S.A. | - PLN | -Infinity% |
| BIOTON S.A. | 181.63 Million PLN | 92.732% |
| Mabion S.A. | 151.67 Million PLN | 91.297% |
| Molecure S.A. | 100.00 PLN | -13200900.0% |
| NanoGroup S.A. | 2019.00 PLN | -653738.534% |
| Pharmena S.A. | 9.83 Million PLN | -34.197% |
| Poltreg S.A. | 1.39 Million PLN | -843.603% |
| Pure Biologics Spólka Akcyjna | 95 Thousand PLN | -13795.789% |
| Ryvu Therapeutics S.A. | 46.86 Million PLN | 71.829% |
| Synthaverse S.A. | 58.6 Million PLN | 77.475% |
| Urteste S.A. | - PLN | -Infinity% |